



FOR IMMEDIATE RELEASE

Tokyo, October 12, 2017

**JT Signs Exclusive License Agreement with EirGen Pharma,
a subsidiary of OPKO, for Development and Commercialization of
Calcifediol Extended-release Capsules in Japan**

Japan Tobacco Inc. (JT) (TSE:2914) announced today that the company has signed an exclusive license agreement with EirGen Pharma Limited (EirGen Pharma) for the development and commercialization in Japan of calcifediol extended-release capsules (marketed by OPKO Health, Inc. (OPKO) in the U.S. under the brand name "RAYALDEE[®]") for the treatment of secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD).

RAYALDEE[®] is a novel extended-release formulation of the prohormone of calcitriol, the active form of vitamin D₃ which reduces elevated intact parathyroid hormone in patients with SHPT without meaningfully affecting serum calcium.

RAYALDEE[®], developed by OPKO, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of SHPT in adults with stage 3 or 4 CKD and vitamin D insufficiency.

Under the terms of the agreement, JT will pay \$6 million in upfront licensing fees, another \$6 million upon initiation of OPKO's planned phase 2 study for RAYALDEE in U.S. dialysis patients, up to an additional \$31 million in regulatory milestones and at the most \$75 million in sales based milestones to EirGen Pharma. In addition, JT will pay royalties based on future sales to EirGen Pharma. Torii Pharmaceutical Co., Ltd., a subsidiary of JT, is expected to commercialize the product once it is approved in Japan.

About OPKO Health, Inc.

OPKO Health, Inc., established in 2007, is a diversified healthcare company focused on developing, manufacturing, and distributing an extensive array of diagnostics and therapeutics for a wide range of indications and conditions. The company is headquartered in Florida, U.S., and is listed on NASDAQ.

For more information, visit www.opko.com.

About EirGen Pharma Limited

EirGen Pharma Limited, established in 2005, is a world-leader in the development, registration, manufacturing and supply of high-potency pharmaceutical products to global markets. The company is headquartered Waterford, Ireland.

For more information, visit www.eirgen.com.

###

Japan Tobacco Inc. is a leading international tobacco company. Its products are sold in over 120 countries and its globally recognized brands include Winston, Camel, Mevius, LD and Natural American Spirit. With diversified operations, JT is also actively present in pharmaceuticals and processed foods. The company's revenue was ¥2.143 trillion (US\$19,703 million^()) in the fiscal year ended December 31, 2016.*

**Translated at the rate of ¥108.78 per \$1*

Contact for Japan Tobacco Inc.:

Masahiro Shirasu, General Manager
Media and Investor Relations Division
Japan Tobacco Inc. Tokyo: +81-3-5572-4292
E-mail: jt.media.relations@jt.com